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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYEpigenetic regulation of key transcriptional programs is a critical mechanism that controls hematopoietic development, and, thus,
aberrant expression patterns or mutations in epigenetic regulators occur frequently in hematologic malignancies. We demonstrate
that the Polycomb protein L3MBTL1, which is monoallelically deleted in 20q- myeloid malignancies, represses the ability of stem cells
to drive hematopoietic-specific transcriptional programs by regulating the expression of SMAD5 and impairing its recruitment to target
regulatory regions. Indeed, knockdown of L3MBTL1 promotes the development of hematopoiesis and impairs neural cell fate in human
pluripotent stem cells. We also found a role for L3MBTL1 in regulating SMAD5 target gene expression in mature hematopoietic cell pop-
ulations, thereby affecting erythroid differentiation. Taken together, we have identified epigenetic priming of hematopoietic-specific
transcriptional networks, which may assist in the development of therapeutic approaches for patients with anemia.INTRODUCTION
L3MBTL1 is the human homolog of the Drosophila tumor
suppressor gene, l(3)mbt (Wismar et al., 1995). The
L3MBTL1 gene is located on the long arm of chromosome
20, within the region that is commonly deleted in hemato-
logic malignancies (Bench et al., 2000, 2004). The crystal
structure of the three MBT domains in human L3MBTL1
exhibited a triple-bladed propeller-like structure (Wang
et al., 2003), and subsequent studies showed that
L3MBTL1 binds to mono- and di-methylated lysines on
histones H1 (H1K26) and H4 (H4K20) via the second
MBT repeat (Kalakonda et al., 2008; Li et al., 2007). Upon
recruitment to the chromatin, L3MBTL1 generally func-
tions as a chromatin compactor and transcriptional
repressor (Boccuni et al., 2003; Kalakonda et al., 2008;
Trojer et al., 2007). Despite its role in affecting chromatin
structure, the function of L3MBTL1 in human hematopoi-
esis had largely remained elusive. Our group and others
have demonstrated that knockdown (KD) of L3MBTL1 re-
sults in the enhanced erythroid differentiation of human
hematopoietic stem/progenitor cells (HSPCs) (Aziz et al.,
2013; Perna et al., 2010), which suggests that haploinsuffi-
ciency of L3MBTL1 contributes to 20q- myeloproliferative
neoplasms.
In the human embryonic stem cells (hESCs), depletion
of L3MBTL1 leads to spontaneous trophoblastic differenti-658 Stem Cell Reports j Vol. 4 j 658–669 j April 14, 2015 j ª2015 The Authoation, a phenotype that mirrors BMP4-treated hESCs
(Hoya-Arias et al., 2011). BMP4 is a critical signaling mole-
cule (Kawabata et al., 1998), directing the hematopoietic
fate from mesoderm during development (Larsson and
Karlsson, 2005; Lengerke et al., 2008; Lohmann and Bieker,
2008;McReynolds et al., 2007; Nostro et al., 2008; Pimanda
et al., 2007; Zafonte et al., 2007). In particular, exogenous
BMP4 can augment the hematopoietic differentiation of
hESCs, and substantially increase the proportion of com-
mitted hematopoietic cells generated from induced plurip-
otent stem cells (iPSCs) (Hong et al., 2011). It is now
believed that a mixture of trophoblast- and mesoderm-
committed cells emerges in response to BMP4 exposure
(Bernardo et al., 2011). BMP4 engages the BMP receptor,
promoting the interaction between its two subunits
(BMPR-IA or IB and II) and triggering the phosphorylation
of SMAD1, SMAD5, or SMAD8 prior to their association
with SMAD4 and their translocation to the nucleus (Mas-
sague´ and Chen, 2000).
Ectopic BMP signaling activates the primitive erythroid
program, while inhibiting the pathway blocks ventral
blood island formation in Xenopus (Zhang and Evans,
1996). This suggests that BMP signaling may represent a
critical influence on erythroid differentiation, in addition
to its role in mesoderm specification (Schmerer and Evans,
2003). In the human adult hematopoietic system, BMP4
mediates regeneration under stress conditions (Lenoxrs
et al., 2005; Trompouki et al., 2011) and the differentiation
of hematopoietic progenitors into erythroid and myeloid
lineages (Detmer and Walker, 2002; Fuchs et al., 2002).
BMP signaling also has been implicated in the malignant
transformation of HSPCs: the recently discovered, cryptic
recurring translocation in pediatric acute megakaryoblastic
leukemia, which leads to fusion of the CBFA2T3 and GLIS2
genes, alters the expression of BMP target genes, leading to
enhanced self-renewal of HSPCs (Gruber et al., 2012).
Here, we demonstrate that depletion of L3MBTL1 primes
human pluripotent stem cells to undergo hematopoietic
fate commitment. We observed increased clonogenic he-
matopoietic potential in the knocked down cells compared
to controls and the early emergence of a primitive CD45
CD31+CD34+ cell population thought to be hemogenic
precursors. Comprehensive assessment of lineage fates in
L3MBTL1-KD pluripotent stem cells showed decreased
expression of endodermal- and ectodermal-specific genes.
We also found impaired development of neural progenitors
by culturing KD embryoid bodies (EBs) with brain-derived
neurotrophic factor (BDNF), which was accompanied by
increased expression of hematopoietic surface markers,
despite the directive cell culture conditions.
The L3MBTL1-KD cells showed an upregulated SMAD5-
mediated transcriptional signature, and we found that
L3MBTL1 regulates the expression of SMAD5 and impairs
its recruitment to target regulatory regions, in both imma-
ture andmature hematopoietic cell populations. Via effects
on the erythroid-specific transcription factor, EKLF,
L3MBTL1, and SMAD5 control the erythroid differentia-
tion of primary cord blood CD34+ cells and hematopoietic
cell lines.RESULTS
KD of L3MBTL1 Primes the Hematopoietic Potential
of iPSCs
The generation of iPSC lines has provided opportunities to
understand the fundamental processes of human cell fate
decisions in the context of tissue regeneration and human
disease. We first observed spontaneous downregulation of
L3MBTL1 expression in a human iPSC line generated
from cord blood cells (iCBCs) (Figures S1A–S1C) upon
mesodermal differentiation, suggesting that decreased
L3MBTL1 expression is required for mesoderm specifica-
tion (Figure 1A). To investigate the role of L3MBTL1 on
the specification of hematopoiesis during iPSC differentia-
tion, we knocked down L3MBTL1 using H1P-hygro-EGFP+
lentiviral vectors that express small hairpin RNAs (shRNAs)
directed against L3MBTL1 (Figure 1B). The subcloned green
fluorescent protein (GFP)+ colonies showed a marked
decrease in L3MBTL1 expression and retained stem cellStemmorphology and stem-cell-related cell surface markers,
including TRA-1-81, KLF4, OCT4, and NANOG expression
(Figures S1D–S1G). Expression of mesoderm-specific tran-
scription factors (T, TAL1, LMO2, and RUNX1) was consis-
tently increased in the KD cells, while key markers for
endoderm and ectoderm decreased (Figure 1C). We
observed downregulation of SOX2 even though the iPSCs
maintained self-renewal properties. While consistent with
a previous report (Wang et al., 2012), we did find upregula-
tion of SOX3 (data not shown), which also could explain
the self-renewal phenotype. Functional assessment of clo-
nogenic hematopoietic progenitors (CFUs) revealed that
the lack of L3MBTL1 induced an increase in hematopoietic
progenitor cell generation (Figure 1D). The hematopoietic
colonies derived from the L3MBTL1-KD cells were also
larger in size (data not shown). CD45CD31+CD34+ cells,
which represent a primitive bipotent endothelial-like pre-
cursor population that is exclusively responsible for he-
matopoietic fate (Wang et al., 2004), were also much
more abundant within the L3MBTL1-KD cells compared
to controls (Figure 1E).
Taken together, these findings indicate that lowering
L3MBTL1 expression primes hematopoietic development
in iPSCs, inducing changes in gene expression that regulate
lineage fate divisions driven by specific differentiation-pro-
moting conditions.
Impaired Development of Neural Progenitors
in L3MBTL1-KD Pluripotent Stem Cells
To assess the neural differentiation potential of the
L3MBTL1-KD cells, we generated EBs and cultured them
in BDNF-containing conditions that support the develop-
ment of neural progenitor cells (Figure 2A, top).While con-
trol EBs developed into Nestin+ neural precursors and Tuj1+
differentiated neurons, L3MBTL1-KD cells showed
impaired neural lineage differentiation (Figure 2A, bottom
and right). The impaired generation of neural precursors is
not dependent on decreased cell proliferation or increased
apoptosis, as we found no significant change in the expres-
sion of Ki-67 and Annexin V (Figures S2A and S2B).
To determine whether L3MBTL1-KD EBs still express he-
matopoietic markers under culture conditions that specif-
ically support neural development, we first assessed CD34
expression using immunofluorescence (IF) and flow cy-
tometry. We found increased CD34 expression in the KD
EBs under conditions that generally promote neural fate
(Figure 2B). Given the general impairment of neural differ-
entiation, the expression of CD31 and TAL1, which are ex-
pressed in hemato-endothelial progenitors (Real et al.,
2012) but also increased in the KD EBs (Figure S2C), sug-
gests the presence of hemogenic precursors. It is possible
that the TAL1+ cells in the L3MBTL1-KD are undifferenti-
ated ESCs within a mixture of cell populations that couldCell Reports j Vol. 4 j 658–669 j April 14, 2015 j ª2015 The Authors 659
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Figure 1. KD of L3MBTL1 Primes the Hematopoietic Potential of iPSCs
(A) Endogenous L3MBTL1 expression was assessed in iPSCs at different time points during the mesodermal, hematopoietic, and erythroid
differentiation using quantitative real-time PCR. The data represent the mean ± SD of the three independent experiments.
(B) Strategy diagram. L3MBTL1 expression is efficiently knocked down as assessed by western blot assay in undifferentiated iPSCs. Tubulin
served as the loading control.
(legend continued on next page)
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not undergo neural development under BDNF-mediated
culture conditions.
Overall, these data indicate that KD of L3MBTL1 pro-
motes hematopoietic development while impairing neural
development.
L3MBTL1 Transcriptionally Represses SMAD5
To investigate the mechanisms underlying the observed
effects of L3MBTL1 on stem cell biology, we utilized an un-
biased, genome-wide approach to analyze the gene expres-
sion profile (GEP) of two independent clones of undifferen-
tiated L3MBTL1-KD iPSCs. We found increased expression
of several BMP/SMAD target genes, as well as downregula-
tion of negative regulators of BMP signaling (Figures 3A
and 3B). ID2 and ID3 were among the upregulated genes,
which are direct targets of BMP4 and regulate HSPC fate de-
cisions (Hong et al., 2011; van Galen et al., 2014). HHEX
also was upregulated; it is known to regulate globin gene
expression during ontogeny and its promoter contains a
71 nucleotide BMP-responsive element (BRE) (Zhang
et al., 2002). We also found increased expression of
ZFP36L2, an RNA-binding protein required for BFU-E self-
renewal (Zhang et al., 2013) (data not shown). Expression
of SMAD7, which inhibits TGFb-related signaling (Nakao
et al., 1997), was downregulated, as were LEFTY1 and
LEFTY2, which function as extracellular antagonists of
Nodal signaling (Yeo and Whitman, 2001).
Analysis of curated pathway gene sets by gene set enri-
chment analysis (GSEA) showed statistically significant
(p < 0.0002; FDR < 0.001) enrichment of SMAD targets as
well as enrichment of three different sets of hematopoietic
stem cell genes (Figures 3C and S3A).We also found enrich-
ment of hematopoietic (non-stem cell) gene sets and
enrichment of hematopoietic transcription factor target
gene sets (Figures S3B and S3C). These data, whichwere ob-
tained from the undifferentiated stage of L3MBTL1-KD
iPSCs, show activation of a hematopoietic cell transcrip-
tional program, fully compatible with the phenotype we
induced by culturing these cells under hematopoietic-spec-
ifying culture conditions. Gene ontology analysis also sup-
ported these findings (Table S1).
To identify which SMAD-regulated signaling pathways
are triggered by L3MBTL1 depletion, we evaluated the(C) KD of L3MBTL1 increases the expression of mesodermal-specific t
endodermal and ectodermal lineages, as shown in L3MBTL1-KD undif
relative expression level of the gene of interest, normalized by GAPDH
versus control cells. The data represent the mean ± SD of the three i
(D) KD of L3MBTL1 increases CFU capacity of iPSC-derived HSCs. Cells
scored after 15 days. The data represent the mean ± SD of the three
(E) KD of L3MBTL1 promotes the emergence of early hemogenic precurs
analyzed by flow cytometry for CD31 and CD34 expression.
Refer to Figure S1 for the characterization of the iPSC line generated
Stemphosphorylation of SMAD1/5 and SMAD2/3, which pri-
marily function downstream of the BMP receptors and
the TGFb, Activin, and Nodal receptors, respectively. We
found enhanced SMAD1/5 phosphorylation (Figure 3D),
indicating that L3MBTL1 titrates BMP signaling.
We also found increased SMAD5 (Figure 3D) and
SMAD1 (Figure S3D) expression in the L3MBTL1-KD cells
compared to controls. Given the transcriptional repressor
functions of L3MBTL1 (Boccuni et al., 2003), we investi-
gated whether L3MBTL1 directly regulates SMAD5 and
SMAD1 expression by performing chromatin immunopre-
cipitation (ChIP) assays. We found recruitment of
L3MBTL1 to regulatory regions of the SMAD5 and
SMAD1 promoters (Figures 3E and S3E), yet the increase
in expression was much higher for SMAD5 than for
SMAD1 and correlated with stronger recruitment of
L3MBTL1 to the SMAD5 than to the SMAD1 target pro-
moter. Consistent with the increased SMAD5 and
SMAD1 expression, ChIP experiments in the L3MBTL1-
KD cells showed fewer repressive histone marks (i.e.,
H3K27me3) at the SMAD5 than at the SMAD1 promoter
(Figures 3F and S3F).
Regulation of SMAD5 by L3MBTL1 Occurs
in Erythroid Cells
We, and others, have suggested that L3MBTL1 plays an
important role in erythroid differentiation of human
CD34+ HSPCs (Aziz et al., 2013; Perna et al., 2010). We
found that downregulation of L3MBTL1 occurs during
normal erythroid differentiation, in a manner similar to
that seen during mesodermal differentiation (Figure 1A).
We first assessed the effect of L3MBTL1-KD in iPSC-derived
CD34+ cells undergoing erythroid differentiation, and
observed a marked acceleration in the expression of the
erythroid-specific marker GlyA (after 2 days in EPO-
induced culture) by flow cytometry in the L3MBTL1-KD
cells (Figure 4A). This was followed by a significant increase
in the expression of several erythroid-specific transcription
factors, especially EKLF (Figure 4B). We also confirmed this
phenotype in b-thalassemic iPSCs (Papapetrou et al.,
2011), which we lentivirally infected to express shRNAs
targeting L3MBTL1 (Figure S4A). Similar to the CB-iPSC
line, knocking down L3MBTL1 in thalassemic erythroidranscription factors while it decreases expression of key markers of
ferentiated iPSCs by qPCR compared to controls. Data indicate the
. The reported fold changes have been calculated by DDCt analysis
ndependent experiments. **p < 0.01 by Student’s t test.
from day 10 hEBs were plated in methylcellulose and colonies were
independent experiments. *p < 0.05 by Student’s t test.
or cells. EBs were harvested at day 10, prior to CD45 emergence, and
from cord blood CD34+ cells.
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Figure 2. Impaired Development of Neural Progenitors in L3MBTL1-KD Pluripotent Stem Cells
(A) KD of L3MBTL1 impairs the ability to form neuronal progenitor cells and neurons. Nestin and Tuj1 expression were evaluated in
EBs by IF. DAPI served as control. (Top) The first line shows multiple EBs at lesser magnification (43); the second line shows a single EB at
103 magnification. (Bottom) The impairment in neural progenitor formation of the L3MBTL1-KD EBs. The graph on the right shows the
(legend continued on next page)
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progeny also increased EKLF expression (Figure S4B) and
increased fetal globin gene expression compared to controls
(Figure S4C).
Ten SMAD-binding motifs were identified within the
upstream enhancer, proximal promoter, and intronic
enhancer of EKLF using EBs (Adelman et al., 2002; Loh-
mann and Bieker, 2008); thus, we investigated whether
L3MBTL1 regulates EKLF gene expression by SMAD5 in
cells that are more mature than pluripotent stem cells.
We found SMAD5 at most of these regions using ChIP as-
says in K562 erythroleukemia cells (Figure 4C, gray bars),
and by retrovirally overexpressing L3MBTL1-HA in K562
cells we found impaired recruitment of SMAD5 to these
EKLF regulatory regions (Figure 4C, blue bars). Further-
more, L3MBTL1 overexpression decreased SMAD5 expres-
sion in K562 cells (Figure S4D).
When we examined primary cord blood CD34+ cells, we
found primarily increased expression of EKLF among
several erythroid-specific genes following KD of L3MBTL1
(Figure 4D).We also found increased globin gene expression
in the L3MBTL1-KD CD34+ cells (Figures 4E and S4E) and
decreased globin expression following overexpression of
L3MBTL1 (Figure 4F). Similar observations were made in
K562 cells (Figures 4G, S4F, and S4G), where we also found
an increase in EKLF expression following L3MBTL1-KD
(Figure S4H).
Overall, these data indicate that the regulation of SMAD
targets by L3MBTL1 occurs inmature erythroid cells as well
as pluripotent stem cells; this effect further promotes
erythroid differentiation.DISCUSSION
This study shows that loss of the Polycomb protein
L3MBTL1 primes human iPSCs for hematopoietic differen-
tiation and enhances commitment toward the erythroid
lineage.Epigenetic Priming of Hematopoietic Lineage
In many biological systems, epigenetic regulation is
important for modulating the expression of critical devel-
opmental genes (Talbert and Henikoff, 2010). For
example, in hESCs, epigenetic priming of genomic regula-
tory regions is an important mechanism underlying thepercentage of EBs containing Tuj1+ cells. The data represent the mean
t test.
(B) KD of L3MBTL1 enhances CD34 expression. (Top left) The first lin
controls; the second line shows a single EB at higher magnification (1
at 43 and 103 magnification is apparent. (Top right) Increased exp
to controls (3%) by FACS is shown. (Bottom right) The graph gives th
mean ± SD of the three independent experiments. *p < 0.05 by Stud
Stemearly specification of future developmental fates. During
the erythroid differentiation of HSPCs, many genes
involved in development and differentiation lose their
H3K27me3 mark, and a fraction of them become enriched
with H3K4me1 and H3K9me1 marks, suggesting that
these genes are poised for activation during the differenti-
ation process (Bernstein et al., 2006; Cui et al., 2009).
Several epigenetic regulatory mechanisms control gene in-
duction and repression during erythroid development
(Hattangadi et al., 2011). The enhancer-mediated recruit-
ment of JMJD3 leads to exclusion of the repressive Poly-
comb repressive complex 2 (PRC2) from the poised
alpha-globin promoter in erythroid cells (Vernimmen
et al., 2011). The L3MBTL1-KD undifferentiated iPSCs dis-
play a GEP that predicts the precocious generation of he-
mogenic precursors and an expansion of induced hemato-
poietic cells under culture conditions that support
hematopoietic cell specification. These changes in gene
expression include upregulation of BMP/SMAD targets
and downregulation of inhibitors of this signaling
pathway, which may mediate, at least in part, a trophecto-
derm versus epiblast decision, as well as a mesoderm
versus ectoderm decision, and finally a non-neural ecto-
derm versus neural ectoderm decision. Accordingly, the
KD iPSCs cannot efficiently generate neural progenitors
under conditions that allow activation of the BMP/
SMAD-signaling pathway. The impaired neural develop-
ment that we observed in L3MBTL1-KD cells supports
the observation that activation of BMP4 signaling is inhib-
itory to the development of non-hematopoietic lineages
(Dee et al., 2007). Consistent with our findings, using
two inhibitors of SMAD signaling, Noggin and
SB431542, one can induce the rapid and nearly complete
conversion of >80% of hESCs to neural cells (Chambers
et al., 2009). This epigenetic silencing mechanism
involving L3MBTL1 also may underlie previous findings
in the L3MBTL1-KD hESCs, which are able to generate
neural progenitors when cultured with SB431542 and dor-
somorphin, strong inhibitors of the SMAD-signaling path-
ways, and spontaneously differentiate toward the tropho-
blast lineage (mirroring the BMP4-treated hESCs) (Hoya-
Arias et al., 2011).
It is possible that a feedback regulatory mechanism of
L3MBTL1 occurs upon the addition of extrinsic BMP4, as
downregulation of L3MBTL1 expression occurs during± SD of the three independent experiments. *p < 0.05 by Student’s
e shows few positive CD34+ EBs at low magnification (43) in the
03). (Bottom left) Increased CD34 staining in the L3MBTL1-KD EBs
ression of CD34 marker (21%) in the L3MBTL1-KD cells compared
e percentage of EBs containing CD34+ cells. The data represent the
ent’s t test. See also Figure S2.
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Figure 3. L3MBTL1 Transcriptionally Represses SMAD5
(A) GEP of undifferentiated L3MBTL1-KD iPSCs, compared to controls, based on microarray analysis. We utilized independent clones of
iPSCs (generated from cord blood CD34+ cells), which we independently infected with lentiviral vectors expressing shRNAs against
L3MBTL1.
(B) mRNA expression levels of several upregulated and downregulated genes, identified by microarray analysis, was confirmed by qPCR.
Data were normalized by GAPDH expression and shown as shRNA versus control. The data represent the mean ± SD of the three independent
experiments.
(C) GSEA for the combined set of SMAD and hematopoietic stem cells genes compared with the differentially expressed genes in L3MBTL1-
KD iPSCs.
(D) Expression levels of phospho SMAD1/5, total SMAD5, phospho SMAD2, total SMAD2, and HHEX were evaluated in L3MBTL1-KD and
control iPSCs by western blot. Tubulin served as the loading control.
(E) iPSCs were crosslinked with 1% formaldehyde and immunoprecipitated with anti-L3MBTL1 or IgG antibody (as a nonspecific control).
Plotted values are relative enrichments (y axis) to 10% input and measured for sites in the SMAD5 promoter and actin (x axis). The data
represent the mean ± SD of the three independent experiments. *p < 0.05 by Student’s t test.
(F) L3MBTL1-KD and control iPSCs were crosslinked with 1% formaldehyde and immunoprecipitated with an anti-H3K27 tri-methyl
antibody or an IgG antibody (as a nonspecific control). Plotted values are relative enrichments (y axis) to 10% input and measured for sites
in the SMAD5 promoter (x axis). The data represent the mean ± SD of the three independent experiments. *p < 0.05 by Student’s t test. See
also Figure S3.mesodermal specification (Figure 1A). This couldmean not
only that mesodermal differentiation requires silencing of
L3MBTL1, but also that BMP4 regulates L3MBTL1 expres-
sion, especially given that changes in culture conditions
(days 6–10) restore the initial levels of L3MBTL1
expression.
An enhanced differentiation toward other non-hemato-
poietic mesodermal lineages, or non-neural ectoderm line-
ages, cannot be excluded in the L3MBTL1-KD cells. Indeed,664 Stem Cell Reports j Vol. 4 j 658–669 j April 14, 2015 j ª2015 The Authowhile GSEA primarily supported our findings (Figure S3B),
we also found significant enrichment of gene sets related to
targets of other PcG proteins in ESCs, such as SUZ12 (Pasini
et al., 2007). These epigenetic signatures regulate establish-
ment of expression programs for ESC differentiation. In
fact, given the diverse signaling pathways that govern he-
matopoietic cell development, it is likely that additional
pathways contribute to hematopoiesis at later stages of
differentiation.rs
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Figure 4. Regulation of SMAD5 by L3MBTL1 Occurs in Erythroid Cells
(A) KD of L3MBTL1 induces early expression of the erythroid-specific marker GlyA in iPSC-derived CD34+ cells. Representative flow
cytometry analysis of iPSCs after 2 days in Epo-induced culture.
(B) Expression levels of EKLF, NF-E2, LMO2, EPOR, and fetal globin gene were assessed in iPSC-derived erythroid progeny by qRT-PCR. Data
were normalized by GAPDH expression. The data represent the mean ± SD of the three independent experiments. **p < 0.01 by Student’s
t test.
(C) K562 erythroleukemia cells were retrovirally transduced to express L3MBTL1-HA (blue bars) or empty MIGR1 control (gray bars),
crosslinked with 1% formaldehyde, and immunoprecipitated with an anti-SMAD5 antibody or IgG antibody. Primers covering the SMAD-
binding motifs (Adelman et al., 2002) across the upstream enhancer, the proximal promoter, and the intronic enhancer of the EKLF were
utilized. Data were normalized by 10% input. The data represent the mean ± SD of the three independent experiments.
(D) EKLF, NF-E2, GATA-1, LMO2, EPOR, and BCL11A expression levels were evaluated by qRT-PCR in L3MBTL1-KD CB CD34+ cells after 7 days of
erythroid-supporting culture (100 ng/ml SCF and 6 U/ml EPO) compared to controls. GAPDH served as a housekeeping gene control. The
data represent the mean ± SD of the three independent experiments. **p < 0.01 by Student’s t test.
(E) Fetal globin levels were evaluated in L3MBTL1-KD CB CD34+ cells by western blot. Tubulin served as the loading control.
(legend continued on next page)
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Transcriptional Networks and Signaling Pathways
in Lineage Specification
Developmental decisions require the integration of a vari-
ety of signaling pathways, and transitions between poised
and active regulatory states are closely integrated with
various developmental signals. There appears to be a close
relationship between core lineage regulators and signaling
pathway outputs. Hence, the genomic binding of transcrip-
tional effectors of TGFb, BMP, andWNT pathways not only
follows the binding ofmaster regulators of lineage identity,
but can be broadly redirected by the overexpression of a
regulatory or lineage-specifying factor for another cell
type (Mullen et al., 2011; Trompouki et al., 2011).
Our study shows that modulation of L3MBTL1 expres-
sion directs lineage-specific gene expression by regulating
the expression of SMAD5 and its recruitment to critical reg-
ulatory regions, such as the erythroid transcription factor
EKLF, allowing it to regulate globin gene expression.
Combinatorial crosstalk among transcription factors is
essential to direct the lineage specification of HSPCs. In
agreement with larger maps of combinatorial interactions
among transcription factors (Ravasi et al., 2010), our work
implies that lineage specification is not completely deter-
mined by tissue-specific transcription factors (such as
EKLF), but can bemodulated by crosstalkwith transcription
factors that are broadly expressed (like SMAD5). A similar ef-
fect is seen in the regulation ofmonocyte differentiation by
SMAD3 (generally expressed) and FLI1 (whose expression is
more restricted primarily to macrophage-related tissues,
such as spleen and lymph nodes) (Ravasi et al., 2010).
We identified SMAD5 as a target of L3MBTL1 and showed
that L3MBTL1 represses its ability to drive target gene
expression. KD of SMAD5 impairs maintenance of the
erythroid program (Fuchs et al., 2002; Liu et al., 2003;
McReynolds et al., 2007), whereas upregulation of EKLF, a
crucial erythroid-specific transcription factor (Alhashem
et al., 2011; Siatecka and Bieker, 2011), occurs in response
to BMP4 treatment in EBs (Adelman et al., 2002; Lohmann
and Bieker, 2008). Here we demonstrated the recruitment
of SMAD5 to these binding sites in definitive hematopoiet-
ic cells and the regulation of EKLF expression and function
via L3MBTL1.
As a readout of EKLF expression and function, we evalu-
ated globin gene expression in definitive hematopoietic
cells, whichwas inversely correlatedwith L3MBTL1 expres-
sion. Increased understanding of how genetic and epige-
netic programs regulate different stages of red blood cell(F) Overexpression of L3MBTL1 decreases globin gene mRNA levels in c
3 days in liquid culture that supports erythroid differentiation. GAPDH
of the three independent experiments. **p < 0.01 by Student’s t test
(G) Overexpression of L3MBTL1 dramatically decreases protein express
assay. Tubulin served as the loading control. See also Figure S4.
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functional RBCs from ESCs and iPSC-derived cells. Hope-
fully, a deeper understanding of the mechanisms regu-
lating erythropoiesis will result in the development of
drugs that are useful in treating patients with erythropoi-
etin-resistant anemias, including bone marrow failure
disorders.EXPERIMENTAL PROCEDURES
Generation and hematopoietic differentiation of human iPSCs
were performed according to previous protocols (Papapetrou
et al., 2011).
Neural Differentiation of EBs
Stem cell colonies were dissociated into single cells using accutase
and cultured in suspension, without any differentiation factors, for
7 to 8 days until they formed three-dimensional multicellular
aggregates. Once EBs formed, they were landed on PO/Laminin/
Fibronectin-coated plates and further differentiated in N2 media
supplemented with BDNF and ascorbic acid. Immunocytochem-
ical and flow cytometry analyses were performed after an addi-
tional 7–14 days in culture.
Purification and in vitro primary culture of human cord blood
CD34+ cells were performed according to previous protocols (Perna
et al., 2010).
Generation of Lenti- and Retroviruses and Cell
Cultures
Lenti- and retroviral vectors were produced by transfection of
293T and Phoenix A cells as previously described (Perna et al.,
2010). Detailed description of the constructs was provided previ-
ously (Kalakonda et al., 2008; Perna et al., 2010). K562 cells were
cultured in RPMI medium supplemented with 10% fetal bovine
serum.
FACS Analysis and Sorting
TransducedCBCD34+ cellswere sorted for green fluorescence (GFP)
and CD34 expression after staining with an APC-conjugated anti-
CD34 antibody (BD340667, Becton Dickinson), using a fluores-
cence-activated cell sorting (FACS) Vantage cell sorter. Cells were
stained with the following antibodies: CD34-APC (BD340667,
BD),CD34-PE (BD348057, BD),CD71-APC (BD561940, BD),Glyco-
phorin A-PE (MHGLA04, Invitrogen), CD31-PE (BD555446, BD),
CD34-PEcy7 (BD560710, BD), and CD45-APC (MHCD4505, Invi-
trogen), and analyzed by FACS. Neural progenitors were stained
with Annexin V (BD556421, BD) and Ki-67 (BD558615, BD) anti-
bodies upon fixation. Isotype-matched antibodies were utilized as
negative controls.ord blood CD34+ cells, as shown by qRT-PCR. Cells were cultured for
served as the housekeeping gene. The data represent the mean ± SD
.
ion levels of gamma globin in K562 cells, as shown by western blot
rs
RNA Extraction and Quantitative Real-Time PCR
For quantitative real-time PCR, total RNAwas isolated from23 105
cells using the RNeasy mini kit (QIAGEN), and then subjected to
reverse transcription with random hexamers (SuperScript III kit,
Invitrogen). Real-time PCR reactions were performed using an
ABI 7500 sequence detection system. A list of PCR primers is avail-
able upon request.
Antibodies
The following antibodies were used for western blot assays: the af-
finity purified anti-L3MBTL1 antibody (described in Kalakonda
et al., 2008), pSMAD1/5 (9516), SMAD1 (6944P), SMAD5 (9517S),
pSMAD2 (3108S), SMAD2 (5339P) (Cell Signaling Technology),
HHEX (Chemicon 10071), EKLF (Abcam 49158), and HA (sc-805).
IF
Cultures were fixed in 4% paraformaldehyde and processed
for immunocytochemistry. The following primary antibodies
were used: Tuj1 (Covance MRB435P-100), Nestin (Neuromics
MO15012), and TAL1 (Abcam 119754).
ChIP Assays
Approximately 43 106 cells were used per ChIP reaction (per anti-
body) after crosslinking with 1% formaldehyde for 10min at room
temperature. ChIP was performed according to the previously re-
ported methodology (Zhao et al., 2008). The associated DNA after
purification was subjected to quantitative real-time PCR to detect
specific DNA sequences. Quantitative results are represented as
percentages to 10%DNA input. The primer sequences are available
upon request.
GEP and GSEA
RNA was extracted and hybridized to Affymetrix Human U133
plus 2.0 arrays, scanned, and subjected to quality control parame-
ters. The GSEA (Subramanian et al., 2005) was performed on 4,722
curated pathway gene sets from the Broad Molecular Signature
Database (http://www.broadinstitute.org/gsea/msigdb/).
ACCESSION NUMBERS
Data have been deposited in the NCBI Gene Expression Omnibus
under accession number GSE65438.
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